SCHEMBL397345

SCHEMBL397345

O=[N+]([O-])c1ccccc1SCl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 4/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAPT P10636 4/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
PKM P14618 1/20 0.49
KDM4A O75164 1/20 0.49
TDP2 O95551 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
ALDH1A1 P00352 6/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GAA P10253 3/20 0.47
LMNA P02545 2/20 0.47
TDP1 Q9NUW8 4/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL4852221 0.89 MAPT (0.50) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL31272173 0.82 PDE7A (0.78) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL875772 0.82 PDE7A (0.78) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL224666 0.82 PDE7A (0.60) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL944057 0.82 TSHR (0.53) PDE7ASMN1; SMN2ALDH1A1TSHRHSD17B10
SCHEMBL1967695 0.82 TDP1 (0.47) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3384869 0.80 PDE7A (0.58) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL1896221 0.80 PDE7A (0.58) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL113566 0.78 PDE7A (0.61) PDE7ASMN1; SMN2MAPTMEN1KMT2A
SCHEMBL2458682 0.78 PDE7A (0.56) PDE7ASMN1; SMN2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 668 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008007807-A1 DIAGNOSTIC BIOMOLECULES SHIMADZU CORPORATION (JP) 2008-01-17 WO claimed
EP-1700114-A4 METHOD FOR ENRICHMENT/SEPARATION OF PROTEIN OR PEPTIDE SHIMADZU CORP (JP) 2007-07-11 EP claimed
US-20070112181-A1 Method for enrichment/seperation of protein or peptide SHIMADZU CORPORATION (JP) 2007-05-17 US claimed
EP-1739419-A1 METHOD OF MEASURING SUBSTANCE BY MASS SPECTROMETRY AND KIT THEREFOR SHIMADZU CORPORATION (JP) 2007-01-03 EP claimed
US-20060243899-A1 Method for selective measurement of specific substances from a mixture by maldi mass spectrometry SHIMADZU CORPORATION 2006-11-02 US claimed
EP-1700114-A2 METHOD FOR ENRICHMENT/SEPARATION OF PROTEIN OR PEPTIDE SHIMADZU CORPORATION (JP) 2006-09-13 EP claimed
US-20050224710-A1 Method for measuring hydrophobic peptides using maldi mass spectrometer SHIMADZU CORPORATION (JP) 2005-10-13 US claimed
WO-2005062725-A2 METHOD FOR ENRICHMENT/SEPARATION OF PROTEIN OR PEPTIDE SHIMADZU CORPORATION (JP) 2005-07-14 WO claimed
EP-0646013-A4 PLATELET DERIVED GROWTH FACTOR ANTAGONISTS. LUDWIG INST CANCER RES (US) 1997-10-15 EP claimed
US-5444151-A Polypeptides containing modified tryptophan units LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 1995-08-22 US claimed
EP-0646013-A1 PLATELET DERIVED GROWTH FACTOR ANTAGONISTS LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 1995-04-05 EP claimed
WO-1993023068-A1 PLATELET DERIVED GROWTH FACTOR ANTAGONISTS LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 1993-11-25 WO claimed
EP-0301376-A1 Rubber vulcanisation process using a vulcanisation system based on 2-nitrophenyl sulphenamides, 2-nitrophenyl sulphenamides, and their preparation BAYER AG (DE) 1989-02-01 EP claimed
US-12613133-B2 Inspection tool and inspection method FUJIFILM CORPORATION (JP) 2026-04-28 US disclosed
US-12436096-B2 Ultraviolet inspection tool and inspection method using a visual indicator FUJIFILM CORPORATION (JP) 2025-10-07 US disclosed
US-12372397-B2 Ultraviolet-sensing member, microcapsule, production method of microcapsule, dispersion liquid for forming ultraviolet-sensing layer, and ultraviolet-sensing kit FUJIFILM CORPORATION (JP) 2025-07-29 US disclosed
US-3993646-A Process for the ring expansion of penicillins to cephalosporin compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1976-11-23 US disclosed
US-3954744-A ANTIBACTERIAL E. R. SQUIBB & SONS, INC. (US) 1976-05-04 US disclosed
US-3932391-A Cephalosporin isocyanates AMERICAN HOME PRODUCTS CORPORATION (US) 1976-01-13 US disclosed
US-3931235-A FROM THE ALKALIMETAL SALT OF 4-HYDROXY-6-METHYL-2-PYRONE AND A THIOLSULFONATE THE DOW CHEMICAL COMPANY (US) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12613133-B2 Inspection tool and inspection method TAS2R30, TAS2R60, TAS2R39 PDE7A 4885/4885SMN1; SMN2 592/4885MAPT 1113/4885
US-20070112181-A1 Method for enrichment/seperation of protein or peptide PTMS, MAX, PREP PDE7A 4415/4885SMN1; SMN2 2607/4885MAPT 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.